“You can get a lot of accolades when you generate positive clinical data, but when you try to launch your own drug, the rubber kind of hits the road. And so a little bit of commercial challenges there for Alnylam.”
Biotech Hangout · Health & Longevity · October 2026
Context
Suvannavejh was explaining Alnylam's post-earnings drop: falling quarterly sales of its newer ATTR drug and a second guidance cut this year. The line is his takeaway for companies moving from R&D to selling their own drug.
Transcript
…with Chinese partners. Now, I don't think there's anything new in any of this, but I would say that it's quite nice that where a pharma company specifically brings it out and says it because we pontificate a lot about what is positive about China. And here's a company that actually tells you. Over.
Great. So, Greg, you want to talk about Al Nylum? We, big stock move this week, a lot of chatter on X about Al Nalim's overall strategy since building a big perch. What was happening?
Yeah, thanks, Chris. Yeah, so on Al Nylum Pharmaceuticals, it's a company I don't really cover, but obviously been following from afar. And what an incredible success story it's overall been. But this week, and for that matter, this year has been really tough for stock performance for the company. The company reported third quarter results. And I think in particular, there were two notable updates that I think sent. the stock um reeling first it was really all about uh the reporting of uh sales for mvotra uh this is their drug for attr um obviously uh it's become a very competitive landscape uh but sales were 81 million dollars in the quarter um and that is versus 129 million dollars in the second quarter so that's a meaningful decline uh again a very competitive market uh the ceo obviously um saying certainly results are not satisfactory um underlying growth demands um and this comes despite them actually increasing uh their sales force recently so that was one bit of bad news and then there was…
yeah for sure i know some of the chatter on x was uh they didn't use their stock currency and position of strength to go into acquisitions right to help them diversify you know their pipeline etc it'll be interesting to see if they start thinking about that you know beyond their their current…
yeah yeah uh happy to chris and and i'm sure we all have uh a lot of commentary on this but uh earlier this week um as i'm pretty sure everyone in the market saw uh anthropic filed an s1 and uh for those of us in the biotech space um you know there's a surprising uh amount of language highlighting…
context around this because i think this conversation is reaching fever pitch, right? It seems. And just a few like almost blog posts that have happened this week. So first, this morning, Bruce Booth posted a really nice article. Again, I'd say old guard perspective on how, Brian, to your point…
More from Biotech Hangout
